Ireland - English - HPRA (Health Products Regulatory Authority)

ranbaxy ireland limited - paracetamol - tablets - 500 milligram

Ireland - English - HPRA (Health Products Regulatory Authority)

ranbaxy ireland limited - paracetamol - tablets - 500 milligram

Canada - English - Health Canada

nora pharma inc - amlodipine (amlodipine besylate) - tablet - 2.5mg - amlodipine (amlodipine besylate) 2.5mg - dihydropyridines

Canada - English - Health Canada

nora pharma inc - amlodipine (amlodipine besylate) - tablet - 5mg - amlodipine (amlodipine besylate) 5mg - dihydropyridines

Canada - English - Health Canada

nora pharma inc - amlodipine (amlodipine besylate) - tablet - 10mg - amlodipine (amlodipine besylate) 10mg - dihydropyridines

Australia - English - Department of Health (Therapeutic Goods Administration)

orion laboratories pty ltd t/a perrigo australia - chloral hydrate, quantity: 100 mg/ml - oral liquid, solution - excipient ingredients: sucrose; citric acid; sodium citrate dihydrate; saccharin sodium; glycerol; methyl hydroxybenzoate; ethanol; propylene glycol; purified water; flavour - indications as at 19 september 2003: chloral hydrate mixture is indicated pre-operatively to produce sedation. it is also indicated for short term (not more than 2 weeks) use as a hypnotic to assist in sleep disorders.

Australia - English - Department of Health (Therapeutic Goods Administration)

well herb pty ltd - angelica dahurica, quantity: 13.986 mg/ml (equivalent: angelica dahurica, qty 120 mg/ml); wolfiporia cocos, quantity: 13.986 mg/ml (equivalent: wolfiporia cocos, qty 120 mg/ml); citrus aurantium, quantity: 13.986 mg/ml (equivalent: citrus aurantium, qty 120 mg/ml; equivalent: oxedrine, qty 30 microgram/ml); atractylodes lancea, quantity: 9.324 mg/ml (equivalent: atractylodes lancea, qty 80 mg/ml); citrus reticulata, quantity: 9.324 mg/ml (equivalent: citrus reticulata, qty 80 mg/ml; equivalent: oxedrine, qty 51 microgram/ml); magnolia officinalis, quantity: 9.324 mg/ml (equivalent: magnolia officinalis, qty 80 mg/ml); pinellia ternata, quantity: 9.324 mg/ml (equivalent: pinellia ternata, qty 80 mg/ml); glycyrrhiza uralensis, quantity: 10 mg/ml (equivalent: glycyrrhiza uralensis, qty 30 mg/ml); pogostemon cablin, quantity: 800 microgram/ml; perilla frutescens, quantity: 40 microgram/ml - oral liquid - excipient ingredients: polysorbate 80; purified water - traditionally used in chinese medicine to clear/dry/drain/eliminate/resolve dampness ; traditionally used in chinese medicine to soothe/descend the arisen stomach-qi ; traditionally used in chinese medicine to clear/expel wind-cold-dampness ; decrease/reduce/relieve diarrhoea ; traditionally used in chinese medicine to decrease/reduce/relieve diarrhoea ; traditionally used in chinese medicine to helps decrease/reduce/relieve symptoms of traveller's diarrhoea ; helps decrease/reduce/relieve symptoms of traveller's diarrhoea ; traditionally used in chinese medicine to harmonise/soothe the stomach ; traditionally used in chinese medicine to antiemetic/decrease/reduce/relieve vomiting ; antiemetic/decrease/reduce/relieve vomiting

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - ciclosporin, quantity: 100 mg/ml - oral liquid, solution - excipient ingredients: dl-alpha-tocopherol; ethanol; corn glycerides; propylene glycol; peg-40 hydrogenated castor oil - as an immunosuppressive agent for the prevention of graft rejection following kidney, liver and heart allogeneic transplantation. for induction and/or maintenance of remission in the nephrotic syndrome. cyclosporin is not a first-line agent. its use should be restricted to occasions when steroids and cystostatic drugs have failed, or are not tolerated, or are considered inappropriate, and when renal function is unimpaired (see warnings). for the treatment of severe, active rheumatoid arthritis in patients for whom classical slow-acting antirheumatic agents (including methotrexate) are inappropriate or ineffective. in patients with severe psoriasis in whom conventional therapy is ineffective or inappropriate and the disease has caused a significant interference with quality of life. additional indication from 11 june 1997: for the treatment of severe atopic dermatitis when other treatment is ineffective or inappropriate.

Australia - English - Department of Health (Therapeutic Goods Administration)

link medical products pty ltd t/a link pharmaceuticals - mercaptopurine monohydrate, quantity: 20 mg/ml - oral liquid, suspension - excipient ingredients: xanthan gum; aspartame; rubus idaeus; sodium methyl hydroxybenzoate; sodium ethyl hydroxybenzoate; potassium sorbate; sodium hydroxide; purified water - allmercap oral liquid suspension is indicated for: treatment of acute lymphoblastic leukaemia (all) in paediatric patients.

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - furosemide, quantity: 10 mg/ml - oral liquid, solution - excipient ingredients: glycerol; purified water; sodium hydroxide; sorbitol solution (70 per cent) (non-crystallising); methyl hydroxybenzoate; ethanol; propyl hydroxybenzoate; sunset yellow fcf; quinoline yellow; flavour - oedema: lasix is indicated in adults, infants and children for the treatment of oedema associated with congestive heart failure, cirrhosis of the liver and renal disease, including the nephrotic syndrome. lasix is particularly useful when an agent with greater diuretic potential than that of those commonly employed is desired. parenteral therapy should be reserved for patients unable to take oral medication or for patients in emergency clinical situations. lasix injection is also indicated as adjunctive therapy in acute pulmonary oedema and cerebral oedema where intense and rapid onset of diuresis is desired. if gastrointestinal absorption is impaired or oral medication is not practical for any reason, lasix is indicated by the intravenous route. parenteral use should be replaced with oral lasix as soon as practical.hypertension. oral lasix may be used in adults for the treatment of hypertension alone or in combination with other antihypertensive agents. hypertensive patients who cannot be adequately controlled with thiazides will probably also not be adequately controlled with lasix alone.